trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'destiny,crc,02']
#asco23
#destinycrc02 phase ii t-dxd 5.4mg/kg dr. raghav orr 37.8% mos 13.4m g3 or higher aes in 49% pts, ild in 8.4% (max g2)
#crc #oncology #research 
Medical Oncologist MD, Vall d'Hebron @vallhebron @VHIO

Vocal Junta Govern @COMBarcelona

Asesor @SalutUIC
#GBM #PhaseI #oncology